Koers InMed Pharmaceuticals Inc Canadian Securities Exchange
Aandelen
IN
CA4576371062
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 7,3 mln. 5,33 mln. 4,96 mln. | Omzet 2025 * | 9,12 mln. 6,66 mln. 6,19 mln. | Marktkapitalisatie | 2,01 mln. 1,46 mln. 1,36 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | - | Nettowinst (verlies) 2025 * | - | EV/omzet 2024 * | 0,27 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 0,22 x |
K/w-verhouding 2024 * |
-
| K/w-verhouding 2025 * |
-
| Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 98,64% |
Recentste transcriptie over InMed Pharmaceuticals Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Eric Adams
CEO | Chief Executive Officer | 61 | 16-06-16 |
Chief Operating Officer | - | 05-11-18 | |
Colin Clancy
IRC | Investor Relations Contact | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Janet Grove
BRD | Director/Board Member | 57 | 11-02-22 |
Eric Adams
CEO | Chief Executive Officer | 61 | 16-06-16 |
Andrew Hull
CHM | Chairman | 61 | 12-09-16 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+8,96% | 105 mld. | |
-1,43% | 104 mld. | |
+4,40% | 22,94 mld. | |
-12,15% | 22,34 mld. | |
-4,36% | 19,25 mld. | |
-39,98% | 17,08 mld. | |
-10,04% | 16,96 mld. | |
+38,61% | 12,63 mld. | |
+313,59% | 8,49 mld. |